Series A

The composite industries have thrived towards sustainability by leveraging the materials strength vs weight to reduce emissions from trains, planes, boats and vehicles. But in the process they generated a large volume of landfill materials from their post industrial excess of technical fibers. in carbon fiber alone, the excess is estimated at 42 thousand metric tons per year. That is about 92.6 million lbs a year of lost resources and supplies at an estimated value > $1B per year.

Globally, more than one billion individuals suffer from neuropsychiatric and mental health disorders, leading to an increased demand for medical help. Approximately 77 million individuals in the U.S. are on antidepressants, anti-anxiety, antipsychotics, and mood stabilizers, and 30% to 60% are treatment-resistant to these drugs.

Petram's mission is to be the most energy efficient rock-breaking technology on Earth. It is our vison to reduce the world's carbon footprint by 1,000,000 tons per year.

Each year, over 51 million surgeries are performed in the United States, each requiring numerous instrument trays to ensure patient safety and surgical efficiency. However, the sterile processing industry is grappling with severe labor shortages, leading to critical errors that can compromise safety and cause significant financial strain. Mistakes in sterile processing contribute to an estimated $25 billion in operating room delays, $16 billion in reprocessing costs, and $3.3 billion in patient infections annually.

SelSym Biotech is a preclinical-stage company focused on improving survivability after severe hemorrhage—the leading cause of death in populations under 45, both domestically and globally.

Most trauma-related deaths occur early due to ineffective bleeding interventions. Current options are limited:

QCarbon Inc. is a deep-tech materials company pioneering the commercialization of QCarbon—a newly discovered phase of carbon stronger than diamond—for clean-energy and high-performance electronic systems.

The Problem

Inhaled nitric oxide (iNO) is a critical therapeutic gas with vasodilatory, anti-inflammatory, and antimicrobial properties, used to treat life-threatening conditions like pulmonary hypertension.

Current delivery systems are complex, costly, and restricted to major medical centers. They rely on highly diluted NO in nitrogen, require specialized scrubbers for toxic NO₂, frequent consumable changes, and large, non-portable equipment—limiting broader adoption and increasing care complexity.

Venous thromboembolism (VTE)—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a leading cause of morbidity and mortality worldwide.

Current standards of care have significant limitations:

The $700 billion natural products market—spanning pharmaceuticals, agriculture/animal health, and consumer health—faces severe production bottlenecks. Many of nature’s most valuable metabolites are produced in trace amounts, blocking clinical trials and cost-effective manufacturing.

Traditional strain improvement is slow and incremental. Even CRISPR delivers only modest gains in genetically intractable microbes.

PolyPV develops lightweight, flexible organic solar modules that deliver reliable power in challenging environments where traditional rigid panels fall short.

The technology addresses a critical need for defense, disaster relief, and remote operators: dependable, portable energy without stable infrastructure. Conventional solar solutions are bulky, fragile, and hard to transport—forcing reliance on heavy batteries or vulnerable fuel supply chains that reduce mobility and increase risk.